

10 B69

FEB. 26. 2002

7:23PM

TOWNSEND&TOWNSEND

**FAX RECEIVED**

NO. 199

P. 1/4

FEB 27 2002

**GROUP 1600**

App. No. 15270J-005910 US

Client Ref. No. 209-US-NEW6

PTO FAX NO.: 1-703-872-9306

ATTENTION: Examiner Sharon Turner

TELEPHONE NO.: 1-703-308-8891

OFFICIAL

Group Art Unit 1647

## OFFICIAL COMMUNICATION

### FOR THE PERSONAL ATTENTION OF

**EXAMINER Sharon Turner**

#### CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following document is being facsimile transmitted to the Patent and Trademark Office (Fax No.: 1-703-872-9306) for the Application of Dale B. Schenk, Application No. 09/585,817, filed June 1, 2000 for PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE on the date shown below.

#### Documents Attached

1. Supplemental Response to Restriction/Election of Species Requirement (3 pages);

Number of pages being transmitted, including this page: 4

Dated: February 26, 2002

  
Rosemarie L. Celli, Reg. No. 42,397

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (650) 326-2400**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
Telephone: 650-326-2400  
Fax: 650-326-2422

FA 3204108 v1

#88/85  
02-27-02

I hereby certify that this correspondence is being facsimile transmitted to  
the U.S. Patent and Trademark Office (Fax No.: 1-703-872-9306)

**PATENT**  
Attorney Docket No.: 15270J-005910US  
Client Ref. No.: 209-US-NEW5

On February 26, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Rosemarie L. Celli

Rosemarie L. Celli

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Dale B. Schenk

Application No.: 09/585,817

Filed: June 1, 2000

For: PHARMACEUTICAL  
COMPOSITIONS AND METHODS FOR  
TREATMENT OF AMYLOID  
DISEASES

Examiner: Sharon Turner

Art Unit: 1647

**SUPPLEMENTAL RESPONSE TO  
RESTRICTION/ELECTION OF SPECIES  
REQUIREMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicant files this Supplemental Response to the Restriction/Election of Species Requirement mailed September 21, 2001 pursuant to today's telephonic interview with Examiner Turner.

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

**IN THE CLAIMS:**

Please amend claim 15.

15. The method of claim 13, wherein said amyloid component is selected from the group consisting of AA, AL, ATTR, AapoA1, Alys, Agel, Acys, A $\beta$ , AB<sub>2</sub>M, AScr, PrP D178N, Acal, AIAPP and synuclein-NAC fragment.